Fig. 6: RETA significantly improves antigen presentation and reduces immunosuppression in the LLC model. | npj Metabolic Health and Disease

Fig. 6: RETA significantly improves antigen presentation and reduces immunosuppression in the LLC model.

From: Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression

Fig. 6

Frequencies of (a), CD45+ cells/live cells (b), CD11b+ cells/CD45+ cells, (c), M-MDSCs/CD45+ cells, (d), PMN-MDSCs/CD45+ cells, (e), macrophages/CD45+ cells, f, MHC II high macrophages/macrophages, g CD3+ cells/CD45+ cells, and (h), CD8+ cells/CD3+ cells are shown. i The mean fluorescence intensity for PD-1 is shown for CD8+ cells. Data is represented as mean ± SEM (N = 7 mice Veh, N = 8 mice RETA).

Back to article page